6 results about "Chronic glomerulonephritis" patented technology

The present invention relates to a pharmaceutical composition for treating chronic glomerulonephritis, its preparation method and application. The pharmaceutical composition is composed of Rhizoma Smilacis Glabrae Albae, Flos Abelmoschi Manihot, Herba Ephedrae Delavayi, Radix Saposhnikoviae Divaricatae, Ramulus Ulmi Pumilae, Herba Dichondrae Repentis, Rhizoma Corydalis Saxicolae, Radix Salviae Yunnanensis, and Radix Achyranthis Aspera. The preparation method is to first extract the above nine herbs with ethanol and then with water, and the mixed solution is concentrated to make a pharmaceutical preparation. The combined use of this pharmaceutical preparation and western medicine can improve the treatment effect of chronic glomerulonephritis, with a total effective rate reaching 84%. Moreover, it can significantly reduce the urinary protein and red blood cells in patients, showing a significant difference compared with the control group using western medicine alone. This indicates that it can effectively improve the clinical symptoms of patients, has no adverse reactions, has high safety, and has extremely high popularization value.

The invention discloses a medicinal moxa composition for preventing and treating codiseases of beriberi and chronic glomerulonephritis. The medicinal moxa composition is prepared from radix aconiti carmichaeli, cortex cinnamomi, cornu cervi pantotrichum, rhizoma alismatis, radix achyranthis bidentatae and moxa. The medicinal moxa composition disclosed by the invention has remarkable external antibacterial and warming effects, consists of five yang warming medicines and one warming medicine, releases volatile components through combustion, and stimulates acupuncture points in combination with heating power, so that the dual effects of treating beriberi and chronic glomerulonephritis are achieved. The radix aconiti carmichaeli, cinnamon, cornu cervi pantotrichum, rhizoma alismatis, radix achyranthis bidentatae and wormwood in the formula form a unique synergistic effect mechanism in the external use process, so that the medicinal components directly reach the focus through skin penetration, and meanwhile, the qi and blood of the whole body are regulated. Through infrared radiation, volatile antibacterial components and a warming effect generated by combustion of the medicinal moxa, the dual treatment effects of external warming and dredging and internal qi and blood regulation are achieved, and a new thought is provided for treatment of foot fungal infection and kidney meridian dysfunction.

The invention discloses an oligopeptide modifier and application thereof in preparation of a medicine for treating and / or improving kidney diseases. The oligopeptide modifier is obtained by replacing any amino acid of oligopeptide with D-type amino acid; the amino acid sequence of the oligopeptide is a conservative replacement variant obtained by adding 1-3 any amino acids to the N terminal and / or C terminal of the amino acid sequence shown as LNLYP or replacing less than 2 amino acids in the amino acid sequence shown as LNLYP with homologous polar amino acids. Experiments prove that compared with LP5, the stability of 145D-LP5 in plasma is remarkably improved, and 145D-LP5 can remarkably improve or treat chronic glomerulonephritis and diabetic nephropathy and inhibit accumulation of advanced glycation end products (AGEs) in kidney tissue.

The invention discloses a traditional Chinese medicine ointment formula for treating kidney deficiency and damp-heat syndrome type chronic glomerulonephritis as well as a preparation method and application thereof. The ointment formula is prepared from astragalus membranaceus, codonopsis pilosula, bighead atractylodes rhizome, donkey-hide gelatin, radix aconiti lateralis preparata, semen cuscutae, eucommia ulmoides, the root of kudzu vine, dried ginger, medicated leaven, rhizoma polygonati, gynostemma pentaphylla, teasel root, lucid ganoderma, divaricate saposhnikovia root, ligusticum wallichii, the root of bidentate achyranthes, parasitic loranthus, deer-horn glue, angelica sinensis, pulp of dogwood fruit, caulis spatholobi, gastrodia elata and pyrrosia lingua. According to the pathogenesis characteristics of the chronic glomerulonephritis, according to clinical practice, treatment based on syndrome differentiation, emphasis on tongue vein change, emphasis on combination of four diagnoses, mastering of yin and yang, and taking flat as a period; five internal organs are harmonized, and spleen and kidney are used as the basis; warm and clear effects are combined, and dynamic and static effects are combined; clinical test results show that after the ointment provided by the invention is used for treatment, the improvement condition of a treatment group is obviously superior to that of a control group, and the total effective rates of the treatment group and the control group in the treatment effect of the traditional Chinese medicine syndromes are 93.3% and 46.7% respectively; therefore, the ointment has a remarkable curative effect in the aspect of relieving the traditional Chinese medicine syndromes of the patients with the kidney-deficiency damp-heat syndrome type chronic nephritis.

The present invention provides a kind of pharmaceutical composition for treating chronic glomerulonephritis, it is the preparation prepared from the following bulk drug by weight ratio: 32-48 parts of Astragalus, 12-18 parts of Codonopsis, 12-18 parts of Rehmannia, 16-24 parts of Cornus, 16-24 parts of Poria, 12-18 parts of Euryale, 12-18 parts of Pyrilaria, 24-36 parts of Leonurus, 12-18 parts of Eucommia, 16-24 parts of Achyranthes, 24-36 parts of Houttuynia, 16-24 parts of Imperata Rhizome, 12-18 parts of Galla, 12-18 parts of Chinese Yam, 4.8-7.2 parts of Oryza Sativa. The present invention also provides the preparation method and purposes of the pharmaceutical composition. The medicine of the present invention belongs to Chinese medicine preparation, and no obvious toxic and side effects are found through clinical studies, and after significantly reducing the urine protein level of the patient, the urine protein level can be well stabilized, which is beneficial to treatment, greatly enhances the patient's treatment enthusiasm, and provides a new medication selection for clinical use.

To provide an ATP production promoter useful for preventing or treating diseases associated with decreased ATP production, particularly renal impairment. [Solution] The present invention comprises an ATP production promoter containing a component having URAT1 inhibitory activity. Preferably, the component having URAT1 inhibitory activity is at least one selected from the group consisting of benzbromarone, probenecid, dotinurad, recinurad, and berinurad. The present invention is expected to be useful as a preventive and therapeutic agent for diseases of decreased ATP production, and is particularly useful as a therapeutic and / or preventive agent for nephrotic syndrome, chronic glomerulonephritis, chronic tubulointerstitial nephritis, chronic pyelonephritis, amyloid kidney, familial juvenile hyperuricemia nephropathy, autosomal dominant tubulointerstitial kidney disease, nephronoplasia, renovascular hypertension, renal vein thrombosis, renal arteriovenous fistula, renal tubular acidosis, Gitelman syndrome, Bartter syndrome, Fanconi syndrome, Lowe syndrome, Alport syndrome, kidney and ureteral stones, and chronic renal failure.